Vir Biotechnology Inc (VIR)
8.21
+0.58
(+7.60%)
USD |
NASDAQ |
Apr 26, 16:00
8.21
0.00 (0.00%)
After-Hours: 20:00
Vir Biotechnology Cash from Operations (TTM): -778.78M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -778.78M |
September 30, 2023 | -635.73M |
June 30, 2023 | -362.00M |
March 31, 2023 | 987.38M |
December 31, 2022 | 1.663B |
September 30, 2022 | 1.636B |
June 30, 2022 | 1.412B |
March 31, 2022 | 592.03M |
December 31, 2021 | -47.59M |
Date | Value |
---|---|
September 30, 2021 | -137.34M |
June 30, 2021 | -81.36M |
March 31, 2021 | -232.06M |
December 31, 2020 | -190.94M |
September 30, 2020 | -147.77M |
June 30, 2020 | -134.89M |
March 31, 2020 | -148.55M |
December 31, 2019 | -129.63M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-778.78M
Minimum
Dec 2023
1.663B
Maximum
Dec 2022
192.00M
Average
-134.89M
Median
Jun 2020
Cash from Operations (TTM) Benchmarks
Vertex Pharmaceuticals Inc | 3.537B |
Vistagen Therapeutics Inc | -26.09M |
Immuneering Corp | -48.97M |
SeaStar Medical Holding Corp | -10.28M |
NovaBay Pharmaceuticals Inc | -4.131M |